Role of Taxoids in Head and Neck Cancer

Schrijvers, Dirk; Vermorken, Jan B.

doi:10.1634/theoncologist.5-3-199

Cited by 40 publications

(32 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…12 The addition of another agent or agents in combination with cisplatin (eg, 5FU or taxanes) concomitant with radiation therapy did not add to the clinical CR rate but increased local side effects, especially mucositis. [4][5][6]10 Thus, cisplatin alone appears to be the chemotherapeutic drug of choice for concurrent chemotherapy with radiation therapy in patients with head and neck cancers. At the present time, cisplatin alone given on a 3-week schedule is the most widely used in the United States.…”

Section: Concurrent Chemoradiotherapymentioning

confidence: 99%

“…The clinical CR rate for the combination of taxanes alone or with other agents given concurrently with radiation therapy is approximately 65%. [4][5][6] However, the local side effects, especially mucositis, are problematic.…”

Section: Concurrent Chemoradiotherapymentioning

confidence: 99%

“…However, the overall survival was not affected by the addition of chemotherapy, despite approximately a 2-year improvement in median survival and about a 9% difference in the actual 5-year survival rate in favor of the chemotherapy group. 5 The lack of statistical significance of benefit reflect the relatively small number of patients included in these trials.…”

Section: Locally Advanced Resectable Cancermentioning

confidence: 99%

See 2 more Smart Citations

Treatment of Locally Advanced Head and Neck Cancer: Historical and Critical Review

Al‐Sarraf

2002

Cancer Control

104

View full text Add to dashboard Cite

Background Advanced squamous cell cancers of the head and neck have traditionally been associated with high rates of morbidity and mortality. Advances in management have improved outcomes for most of these patients. Methods The author reviews the historical progress in management of these difficult tumors and adds his own wide experience to describe and evaluate newer approaches to management. Results Over the last 10 years, overall survival rates for patients with head and neck cancers have improved as has quality of life. New standards of care have been defined for patients with nasopharyngeal cancer and for those with advanced unresectable disease. Organ preservation is more commonly achieved. Conclusions Newer targeted therapies are likely to add to the progress that has already been achieved in the multimodality management of patients with head and neck cancers.

show abstract

Section: Concurrent Chemoradiotherapymentioning

confidence: 99%

Section: Concurrent Chemoradiotherapymentioning

confidence: 99%

Section: Locally Advanced Resectable Cancermentioning

confidence: 99%

See 1 more Smart Citation

Treatment of Locally Advanced Head and Neck Cancer: Historical and Critical Review

Al‐Sarraf

2002

Cancer Control

104

View full text Add to dashboard Cite

show abstract

“…Both taxol and brefeldin A have been demonstrated to induce apoptosis of the C5 cell line. 41 Etoposide is a genotoxin that inhibits DNA repair, 42 whereas the site of action for taxol is the microtuble network, 43 and brefeldin A acts upon the Golgi and trans-Golgi network. 44 All three are considered to activate the 'intrinsic' apoptotic pathway.…”

Section: Igf1 Treatment Suppressed Apoptosis Induced By Other Agentsmentioning

confidence: 99%

Synergistic suppression of apoptosis in salivary acinar cells by IGF1 and EGF

et al. 2003

View full text Add to dashboard Cite

Tissue homeostasis requires balancing cell proliferation and programmed cell death. IGF1 significantly suppressed etoposide-induced apoptosis, measured by caspase 3 activation and quantitation of cellular subG 1 DNA content, in rat parotid salivary acinar cells (C5). Transduction of C5 cells with an adenovirus expressing a constitutively activated mutant of Akt-suppressed etoposide-induced apoptosis, whereas a kinase-inactive mutant of Akt suppressed the protective effect of IGF1. IGF1 also suppressed apoptosis induced by taxol and brefeldin A. EGF was unable to suppress apoptosis induced by etoposide, but was able to synergize with IGF1 to further suppress caspase 3 activation and DNA cleavage after etoposide treatment. The catalytic activity of Akt was significantly higher following stimulation with both growth factors compared to stimulation with IGF1 or EGF alone. These results suggest that a threshold of activated Akt is required for suppression of apoptosis and the cooperative action of growth factors in regulating salivary gland homeostasis.

show abstract

“…The major toxicity associated with docetaxel is highly predictable myelotoxicity (Posner, 2001a). More importantly, neuropathy, a dominant side effect of cisplatin, is minimal with docetaxel-containing regimens, but can be significant in paclitaxel-containing regimens (Schrijvers and Vermorken, 2000;Colevas and Posner, 2001;Posner, 2001a). The differing mechanisms of action, and relative nonoverlapping toxicities compared with PF, have prompted interest in the addition of docetaxel to PF regimens.…”

mentioning

confidence: 99%

Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck

Posner

Lefèbvre

2003

Br J Cancer

View full text Add to dashboard Cite

Patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) are often treated with induction chemotherapy or chemoradiotherapy, but to date without major impact on survival. The combination of cisplatin -5-fluorouracil (5-FU) (PF) has been used as standard induction therapy; however, poor patient survival has stimulated investigation into new agents with potential activity in SCCHN. Docetaxel has significant single-agent activity in SCCHN and has been investigated in combination with PF regimens as induction therapy. The results of six phase II studies of docetaxel -PF regimens (TPF) as induction in locally advanced SCCHN patients are reviewed and reported. Consistently, high 2-year survival rates and overall response rates were demonstrated across the phase II trials in the range 42 -82 and 71 -100%, respectively. The toxicity profile seen with TPF-based regimens was acceptable. The primary toxicity was neutropenia, which together with gastrointestinal complaints accounted for the majority of adverse events. Given the encouraging phase II experience with TPF-based regimens, two large-scale phase III studies comparing TPF-based regimens with standard PF regimens are underway. The results have significant potential for validating the findings of the phase II studies, demonstrating improved survival and overall response of patients treated with docetaxel-based induction chemotherapy.

show abstract

Role of Taxoids in Head and Neck Cancer

Cited by 40 publications

References 38 publications

Treatment of Locally Advanced Head and Neck Cancer: Historical and Critical Review

Treatment of Locally Advanced Head and Neck Cancer: Historical and Critical Review

Synergistic suppression of apoptosis in salivary acinar cells by IGF1 and EGF

Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck

Contact Info

Product

Resources

About